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ABSTRACT
Mycosis fungoides, the most common subtype of cu-
taneous T-cell lymphoma, displays a broad spectrum 
of clinical, histological and phenotypic variants with 
different prognostic impacts. The classic immunopheno-
type is CD3+/CD4+/CD45RO+memory T cells. CD4/
CD8 double-negative mycosis fungoides is rare. Here 
we describe the clinicopathological features of CD4/
CD8 double-negative mycosis fungoides in a 55-year-
old female with a review of the literature. Although the 
CD4/CD8 double-negative phenotype appears to be 
associated with an unusual clinical presentation, it does 
not appear to confer prognostic significance.
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Although mycosis fungoides (MF) accounts for less than 
1% of all non-Hodgkin lymphomas, MF is by far the 
most predominant cutaneous T-cell lymphoma subtype.1 
Management of MF is based on the TNM classification 
categorized into 4 clinical stages.2 In addition, MF is 
classically divided according to its clinical presentation 
as patches in the early stage, plaques in the middle stage 
and tumors in the late stage.3 The clinical course and 
prognosis are depend on skin symptoms, and a mixture 
of those eruptions is usually seen during in its long clini-
cal time course.1 Any area of skin may be affected in the 
early phases, and diagnosis is difficult. It is most often 
misdiagnosed as atopic dermatitis, psoriasis or chronic 
eczema, especially in the early stage.4 Since MF also 
resembles parapsoriasis en plaques, the definition and 
characterization of the early stage of MF is difficult.5 
Occasionally, a plaque may ulcerate prior to the tumor 
stage.6 Patches and plaques may show poikiloderma in-
cluding hypopigmentation, hyperpigmentation, atrophy 
and teleangiectasia.7 Other reported subtypes according 
to clinical, histological and immunological characteris-
tics include erythrodermic, poikilodermic, purpura pig-
mentosa and papuloerythroderma types and a leukemic 
variant of MF.8–11
 MF is a neoplasia of lymphocytes that generally co-
incides with cutaneous lymphoma originating in epider-
motropic T cells, which express the T cell receptor with 
αβ+subunits and CD4+ immunophenotype, known as 
CD45RO+memory T-lymphocytes. Although a definitive 
diagnosis of MF may be made on the basis of clinical 
and histopathological features, determination of T-cell 
clonality and immunophenotypical analysis of T cells by 
immunohistochemistry or flowcytometry are important. 
MF is generally of the CD3+, CD4+, CD45RO+ and 
CD8- phenotype, which is a cytokine production pattern 
with a Th2 profile. However, a broad range of MF vari-
ants with differential diagnosis have been described, and 
some of them have different immunophenotypic profiles. 
Thus, understanding the immunophenotype based on 
the clinical features and staging is important for long-
term follow-up. 
PATIENT REPORT 
A 55-year-old female presented with a 2-month history 
of an enlarged red nodule on her right thigh (Fig. 1a). 
She had a 30-year history of asymptomatic erythema 
on her trunk and extremities. Physical examination 
revealed multiple round to oval scaly erythematous 
patches and plaques of up to 15 cm in size on her whole 
body and mixed hypo-and hyperpigmented small 
patches disseminated on her trunk (Figs. 1b and c). A 
3 cm subcutaneous indurated nodule was seen on her 
right thigh. A skin biopsy specimen from the right thigh 
showed dense infiltration of atypical lymphocytes in the 
subcutaneous tissue to the epidermis (Fig. 2a). The le-
sion disappeared after biopsy. Another biopsy specimen 
from a patch on her left leg showed mild acanthosis, 
dermal infiltration of small lymphocytes with prominent 
epidermotropism, and Pautrier’s microabscess (Figs.1d 
and 2b). Immunohistochemically, the tumor cells were 
positive for CD3, CD45RO and CD5 but were negative 
for CD7, CD4, CD8, CD30, CD20 and T-cell restricted 
intracellular antigen-1 (TIA-1) (Figs. 2c–e). Molecular 
biology investigations indicated a monoclonal rearrange-
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Fig. 1. a: Red nodule on her right thigh. b: Disseminated hypopigmented and hyperpigmented small patches. c: Multiple round to oval 
erythematous patches and plaques. d: Erythematous patches on her left leg.
ment of the T-cell receptor beta gene. The peripheral 
blood cell count was normal, and there were no atypical 
cells. Neither internal organ involvement nor lymph-
adenopathy was detected by computed tomography. 
Based on these fi ndings, we made a diagnosis of CD4/
CD8 double-negative mycosis fungoides of stage ⅡB. 
The patient was treated with a topical corticosteroid and 
narrow-band ultraviolet B (NBUVB). 
DISCUSSION
Mycosis fungoides is a cutaneous T cell lymphoma with 
an indolent course and typically affects older adults 
(median age at diagnosis: 55–60 years; male-to-female 
ratio: 1.6–2.0:1).1 A total of 34 cases of CD4/CD8 double 
negative MF have been reported.12–16 Clinical features of 
the patients are summarized in Table 1. The patients in-
cluded 14 males and 12 females, and the age at diagnosis 
ranged from 12 to 82 years (mean: 47.3 years). The du-
ration of disease before diagnosis ranged from 6 months 
to 30 years (mean: 8.5 years). Eight patients had classic 
MF and 13 presented with unusual clinical variants: 
hypopigmented in 7 patients, localized in 3 patients, ich-
thyosiform in one patient, purpuric in one patient and er-
ythema gyratum repens-like in one patient. Twenty-eight 
cases were early stage at diagnosis and 4 cases were 
advanced stage. Treatment was topical steroids, psoralen 
and ultraviolet A (PUVA), NBUVB or radiation. Four 
patients received interferon or chemotherapy in addition 
to skin-target therapy. The clinical course was indolent 
except for 3 cases: advanced stage at diagnosis due to 
lymph node and bone marrow metastasis in case 2, liver 
metastasis in case 4 and large cell transformation in case 5.
 The histopathology of classic MF in the patch/
plaque stage shows superfi cial bandlike or lichenoid in-
fi ltration of lymphocytes and histiocytes. Atypical cells 
are small to medium-sized, highly indented (cerebriform) 
and mostly confi ned to the epidermis (epidermotropism). 
They are characteristically present in the basal layer of 
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revealed that the age at diagnosis was younger and the 
male-to-female ratio was smaller than those in patients 
with conventional MF. Hodak et al. reported that most of 
the CD4/CD8 double-negative MF cases were clinically 
characterized by an unusual clinical presentation.13 We 
also found the same results in our review. Especially, 
the hypopigmented type was most commonly seen and 
occurred at younger ages than the other types. This was 
consistent with the characteristics of the hypopigmented 
MF already reported as having a good prognosis in 
young age.18
 Clonal T cell receptor gene rearrangement was 
detected in 57–71% of cases of early lesions of MF and 
was not related to prognosis.15 In some cases of CD4/
CD8 double-negative MF, the cells expressed cytotoxic 
markers such as TIA-1 and CD56. Although a cytotoxic 
phenotype was occasionally seen in MF, clinical behav-
ior did not differ from conventional MF.19–21
 The prognosis of patients with MF depends on the 
Fig. 2. a: Skin biopsy specimen from a nodule on her right thigh. Bar = 500 µm. b: Skin biopsy specimen from a patch on left leg. (hematoxylin-
eosin stain). Bar = 50 µm. c: Immunohistochemical staining for CD3. Bar = 50 µm. d: Immunohistochemical staining for CD4. Bar = 50 
µm. e: Immunohistochemical staining for CD8. Bar = 50 µm.
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the epidermis either as single and often haloed cells or 
in a linear confi guration. The presence of intraepidermal 
collections of atypical cells (Pautrier microabscesses) 
is a highly characteristic feature but is not always 
observed.17 In cases of CD4/CD8 double-negative MF, 
histopathology is almost the same as that of the conven-
tional type. 
 Table 2 summarizes the immunophenotypes of neo-
plastic cells. Deletion of CD7 was observed in 23 of the 
29 cases tested. CD45RO, a memory phenotype marker, 
was expressed in 18 (69%) of 26 cases and TIA-1, a 
cytotoxic phenotype marker, was expressed in 11 (65%) 
of 17 cases. CD56 was positive in 2 (7%) of 28 cases, 
and CD30 was positive in 6 (20%) of 30 cases. T-cell 
clonality was evaluated in 21 cases by detection of a 
monoclonal rearrangement of T cell receptor gamma or 
beta gene using a polymerase chain reaction technique. 
Monoclonality was detected in 15 (71%) of 21 cases.  
 Our review of CD4/CD8 double-negative MF cases 
156
A. Ito et al.
Table 1. Clinical data
Case Age/Sex Duration (Y) Stage Clinical subtype Treatment
Prognosis and  survival 
(Y)
1 72/M NA Plaque NA PUVA,etretinate, and chemotherapy CR 1.4
2 77/F NA Tumor NA PUVA, X-ray and chemotherapy Death 6.8
3 52/F NA Tumor NA PUVA PR 14.0
4 82/F NA Tumor NA PUVA, X-ray and chemotherapy Death 3
5 NA NA ⅡB NA Chemotherapy Death 3.9
6 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
7 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
8 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
9 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
10 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
11 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
12 NA NA ⅠA/ⅠB NA PUVA/X-ray /IFNα Indolent course
13 77/M 3 ⅠB Classic Skin target therapy Indolent course
14 12/M 5 ⅠB Hypopigmented Skin target therapy Indolent course
15 38/F 4 ⅠB Hypopigmented Skin target therapy Indolent course
16 11/M 9 ⅠB Hypopigmented Skin target therapy Indolent course
17 45/M 4 Patch Localized/Unilesional Skin target therapy Indolent course
18 72/M 15 ⅠA Classic Skin target therapy Indolent course
19 71/F 0.5 ⅠB Classic Skin target therapy Indolent course
20 61/F 10 ⅠA Classic Skin target therapy Indolent course
21 28/M 2 ⅠB Classic Skin target therapy Indolent course
22 55/M 10 ⅠB Classic Skin target therapy Indolent course
23 47/M 20 ⅠA Classic Skin target therapy Indolent course
24 73/F 10 Plaque Localized/Unilesional Skin target therapy Indolent course
25 14/F 10 ⅠA Hypopigmented Skin target therapy Indolent course
26 27/M 9 ⅠB Classic Skin target therapy Indolent course
27 14/M 12 ⅠB Hypopigmented Skin target therapy Indolent course
28 14/M 8 ⅠB Ichthyosiform Skin target therapy Indolent course
29 34/F 1 Plaque Localized/Pagetoid reticulosis Skin target therapy Indolent course
30 34/M 2 ⅠB Classic and purpuric Skin target therapy Indolent course
31 23/F NA NA NA NA NA
32 45/F NA NA NA NA NA
33 70/F 5 ⅠB Hypopigmented NBUVB PR
34 73/M 10 ⅠB Erythema gyratum repens -like PUVA PR
Our case 55/F 30 ⅡB Hypopigmented NBUVB Indolent course
CR, complete response; F, female; IFN, interferon; M, male; NA, not applicable; NBUVB, narrow-band ultraviolet B; PR, partial re-
sponse; PUVA, psoralen ultraviolet A; Y, years.
stage and particularly on the type and extent of skin le-
sions and the presence of extracutaneous disease.22, 23 The 
5-year disease-specific survival rates were reported to be 
73%-96% for patients in the patch/plaque stage and 44% 
for patients in the tumor stage.23 Patients with effaced 
lymph nodes, visceral involvement and transformation 
into a large T-cell lymphoma have an aggressive clin-
ical course.1 The clinical course of CD4/CD8 double-
negative MF was indolent except for 3 patients with an 
advanced stage at diagnosis and it was the same as that 
of conventional MF.  
 As long as the disease is confined to the skin, 
skin-targeted therapies are preferred. In patients with 
early stage MF (1A1B2A), topical corticosteroids, UVB, 
PUVA, localized radiotherapy or interferon gamma 
can be used.24, 25 Systemic therapy such as treatment 
with retinoids, interferon alpha, low-dose MTX or 
chemotherapy should be mainly considered for patients 
with advanced stages or for patients with refractory cu-
taneous disease.26, 27 Biologicals such as interferon alpha 
and other cytokines, traditional and new retinoids such 
as bexarotene, and receptor-targeted cytotoxic fusion 
proteins, are being increasingly used in the treatment of 
MF.28 
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Table 2. Immunophenotype of intraepidermal atypical lymphocytes
Case CD3 CD4 CD8 CD7 CD45RO TIA-1 CD56 CD30 TCR-β TCR-δ Clonality
1 + – – NA NA NA NA + + – NA
2 + – – + NA NA NA – + – NA
3 + – – – NA NA NA – + – NA
4 + – – – NA NA NA – – + NA
5 3+ – – 2+ – NA 2+ – 3+ – NA
6 3+ – – – 2+ NA – – 3+ – NA
7 3+ – – – – NA – 2+ – 3+ NA
8 - – – – 2+ NA – 2+ 3+ – NA
9 3+ – – 2+ – NA 2+ 2+ – – NA
10 3+ – – – – NA – – – 3+ NA
11 3+ – – 2+ – NA – 2+ – 3+ NA
12 3+ – – 2+ – NA – – 3+ – NA
13 3+ – – – 3+ 3+ – – 2+ – +
14 3+ – – – 3+ 3+ 3+ – 2+ – NA
15 3+ – – – 3+ – – – – – +
16 3+ – – – – 3+ – – NA NA +
17 3+ – – – 3+ NA – – – – +
18 3+ – – – 3+ – – – – 1+ +
19 3+ – – – 3+ – – – 3+ – –
20 3+ – – – 3+ 3+ – – – – –
21 3+ – – – 3+ 3+ – – 2+ – +
22 3+ – – – 3+ 3+ – – – – +
23 3+ – – – 3+ NA – – 2+ 1+ +
24 3+ – – – 3+ 3+ – 1+ – 3+ –
25 3+ – – – 3+ 3+ – – NA NA NA
26 3+ – – – 3+ 3+ – 2+ – – –
27 3+ – – – 3+ 3+ – – – 1+ –
28 3+ – – NA NA NA NA NA 1+ – +
29 3+ – – – NA NA NA NA 3+ – –
30 3+ – – – 3+ 1+ – – 3+ – +
31 NA – – NA NA – – NA + NA +
32 NA – – NA NA – – NA + NA +
33 3+ – – 3+ – – – – – – +
34 + – – NA + NA NA NA NA NA +
Our case 3+ – – – 3+ – – – + NA +
–; < 10%, 1+; < 25%, 2+; < 50%, 3+; > 50%. NA, not applicable; TCR, T cell receptor; TIA-1, T cell intracellular antigen 1.
 Our patient had a hypopigmented type and indolent 
course, which was typical of case in a review of CD4/
CD8 double-negative MF cases. 
 In conclusion, CD4/CD8 double-negative MF is 
a rare immunophenotype of MF. Unusual phenotypes 
and clinical presentations sometime make diagnosis of 
MF difficult. It is important to consider variants such as 
CD4/CD8 double-negative MF, and clinicopathologic 
correlation is always required. 
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